 Experience third-generation implantable cardioverter-defibrillator Medtronic pacemaker cardioverter-defibrillator patients mean age years sustained ventricular tachycardia VT ventricular fibrillation VF organic heart disease mean ventricular ejection fraction Endocardial epicardial defibrillation shock efficacy implant shock patterns monophasic single sequential simultaneous shocks dual triple electrode configurations Endocardial leads common right ventricular cathode dual anodes epicardial leads helical coil patches VT termination pacing shock therapy shocks VF Programmable bradycardia pacing individual zones VT VF detection individualized pacing shock therapy VT VF Monophasic shocks epicardial defibrillation thresholds comparable sequential simultaneous shocks VT detection rates ms VF detection rates VT VF induction patients implant rapid patients low-energy shocks patients high-energy shocks patients therapy patients Intermediate high-energy shocks induced VF episodes follow-up months noncardiac deaths Electrical therapy patients VT patients VT VF patients indeterminate tachyarrhythmia patient VT/VF episodes spontaneous VT episodes Follow-up reprogramming patients successful application individualized electrical therapy prescriptions patients VT/VF feasible therapies effective induced VT effective long-term spontaneous VT termination conjunction shock therapy patient exposure therapy programmable hybrid pacemaker cardioverter-defibrillator system nonthoracotomy implantation effective VT/VF termination demand ventricular pacing noninvasive modes arrhythmia induction event monitoring clinical trouble-shooting